Research Article| Volume 276, ISSUE 1-2, P18-21, January 15, 2009

Download started.


Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson's disease and of l-dopa-induced adverse effects


      Sporadic Parkinson's disease (PD) is a frequent neurodegenerative movement disorder. Both environmental and genetic factors have been studied in the etiology of PD. Among genetic factors, increasing evidences suggest that deletion/insertion (D/I) gene polymorphism of the angiotensin I-converting enzyme (ACE) may be involved in the pathogenesis of PD and in the occurrence of the adverse effects of chronic l-dopa therapy. We investigated this hypothesis by evaluating the frequency of the ACE gene D/I polymorphism in 120 Italian PD patients and 132 controls. Out of the 120 PD patients, 91 were under chronic l-dopa treatment. Our results revealed no difference in ACE I/D genotype (χ2=0.79, p=0.66) and allele (χ2=0.34, p=0.56) frequencies between PD and controls. We also failed to observe any significant association with the occurrence of l-dopa-induced adverse effects in long-term treated PD patients, thereby excluding the presence of an association between ACE I/D genotypes and the genetic susceptibility to PD and the development of adverse effect of chronic l-dopa therapy.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • De Rijk M.C.
        • Launer L.J.
        • Berger K.
        • Breteler M.M.
        • Dartiques J.F.
        • Baldereschi M.
        • et al.
        Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts.
        Neurology. 2000; 54: S21-S23
        • Tanner C.M.
        Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies.
        Adv Neurol. 2003; 91: 133-142
        • Mizuno Y.
        • Hattori N.
        • Kitada T.
        • Matsumine H.
        • Moti H.
        • Shimura H.
        • et al.
        Familial Parkinson's disease. Alpha-synuclein and parkin.
        Adv Neurol. 2001; 86: 13-21
        • Gwinn-Hardy K.
        Genetics of parkinsonism.
        Mov Disord. 2002; 17: 645-656
        • Markopoulou K.
        • Langston J.W.
        Candidate genes and Parkinson's disease: where to next?vol. 53. 1999: 1382-1383
        • Gasser T.
        Genetics of Parkinson's disease.
        J Neurol. 2001; 248: 833-840
        • Olanow C.W.
        • Watts R.l.
        • Koller W.C.
        An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines.
        Neurology. 2001; 56: S1-S88
        • Kaiser R.
        • Hofer A.
        • Grapengiesser A.
        • Gasser T.
        • Kupsch A.
        • Roots I.
        • et al.
        l-dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.
        Neurology. 2003; 60: 1750-1755
        • Goetz C.G.
        • Burke P.F.
        • Leurgans S.
        • Berry-Kravis E.
        • Blasucci L.M.
        • Raman R.
        • et al.
        Genetic variation analysis in Parkinson's disease patients with and without hallucinations: case–control study.
        Arch Neurol. 2001; 58: 209-213
        • Wang J.
        • Liu Z.L.
        • Chen B.
        Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD.
        Neurology. 2001; 56: 1757-1759
        • Lin J.J.
        • Yueh K.C.
        • Lin S.Z.
        • Harn H.J.
        • Liu J.T.
        Genetic polymorphism of the angiotensin converting enzyme and l-dopa-induced adverse effects in Parkinson's disease.
        J Neurol Sci. 2007; 252: 130-134
        • Skidgel R.A.
        • Defendini R.
        • Erdos E.G.
        Angiotensin I-converting enzyme and its role in neuropeptide metabolism.
        in: Turner A.J. Neuropeptides and their peptidases. Ellis Horwood, New York1987: 165-182
        • Campbell D.J.
        The renin–angiotensin and the kallikrein–kinin systems.
        Int J Biochem Cell Biol. 2003; 35: 784-791
        • Whitton P.S.
        Inflammation as a causative factor in the aetiology of Parkinson's disease.
        Br J Pharmacol. 2007; 150: 963-976
        • Barker R.
        Substance P and Parkinson's disease: a causal relationship?.
        J Theor Biol. 1986; 120: 353-356
        • Jenkins T.A.
        • Mendelsohn F.A.
        • Chai S.Y.
        Angiotensin-converting enzyme modulates dopamine turnover in the striatum.
        J Neurochem. 1997; 68: 1304-1311
        • Jenkins T.A.
        • Allen A.M.
        • Chai S.Y.
        • MacGregor D.P.
        • Paxinos G.
        • Mendelsohn F.A.
        Interactions of angiotensin II with central dopamine.
        Adv Exp Med Biol. 1996; 396: 93-103
        • Konings C.H.
        • Kuiper M.A.
        • Bergmans P.L.
        • Grijpma A.M.
        • van Kamp G.J.
        • Wolters E.C.
        Increased angiotensin-converting enzyme activity in cerebrospinal fluid of treated patients with Parkinson's disease.
        Clin Chim Acta. 1994; 231: 101-106
        • Reardon K.A.
        • Mendelsohn F.A.
        • Chai S.Y.
        • Horne M.K.
        The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease.
        Aust N Z J Med. 2000; 30: 48-53
        • Rigat B.
        • Hubert C.
        • Alhenc-Gelas F.
        • Cambien F.
        • Corvol P.
        • Soubrier F.
        An insertion-deletion polymorphism in angiotensin-converting enzyme gene accounting for half the variance of serum enzyme levels.
        J Clin Invest. 1990; 86: 1343-1346
        • Mellick G.D.
        • Buchanan D.D.
        • McCann S.J.
        • Davis D.R.
        • Le Couteur D.G.
        • Chan D.
        • et al.
        The ACE deletion polymorphism is not associated with Parkinson's disease.
        Eur Neurol. 1999; 41: 103-106
        • Lin J.J.
        • Yueh K.C.
        • Chang D.C.
        • Lin S.Z.
        Association between genetic polymorphism of angiotensin-converting enzyme gene and Parkinson's disease.
        J Neurol Sci. 2002; 199: 25-29
        • Daniel S.E.
        • Lees A.J.
        Parkinson's Disease Society Brain Bank, London: overview and research.
        J Neurol Transm Suppl. 1993; 39: 165-172
        • Castellano M.
        • Glorioso N.
        • Cusi D.
        • Sarzani R.
        • Fabris B.
        • Opocher G.
        • et al.
        Genetic polymorphism of the renin–angiotensin–aldosterone system and arterial hypertension in the Italian population: the GENIPER project.
        J Hypertens. 2003; 21: 1853-1860
        • Cambien F.
        The angiotensin-converting enzyme (ACE) genetic polymorphism: its relationship with plasma ACE level and myocardial infarction.
        Clin Genet. 1994; 46: 94-101
        • Holmer S.R.
        • Bickeboller H.
        • Hengstenberg C.
        • Rohlmann F.
        • Engel S.
        • Lowel H.
        • et al.
        Angiotensin converting enzyme gene polymorphism and myocardial infarction a large association and linkage study.
        Int J Biochem Cell Biol. 2003; 35: 955-962
        • Lin J.J.
        • Yueh K.C.
        • Harn H.J.
        • Chang C.Y.
        • Yeh Y.H.
        Lack of association between deletion polymorphism of the ACE gene and ischemic vascular diseases in a Chinese population in Taiwan.
        Chin Med J (Taipei). 1999; 62: 756-763